By SETH J. FRANTZMAN
ISRAEL, July 2, 2020
Document 1: IAI press releease
A Historic Agreement-
IAI will partner with the United Arab Emirates, signing an agreement to develop breakthrough technology solutions for the Covid-19 epidemic with Group42 from Abu Dhabi. IAI has signed a historic collaboration agreement with Group 42 of Abu Dhabi, the capital of the United Arab Emirates. The companies will collaborate in the research and development areas to find solutions to help combat the coronavirus disease.
The cooperation agreement was signed with the Elta Division, via video call between the UAE and Israel, during which ways to leverage common innovative technologies in the fields of artificial intelligence, sensing, laser and more. The state-of-the-art solutions and joint medical and technological initiatives are aimed not only at the population of the two countries, but to aid the global fight in Covid-19 and the health security of the entire region.
IAI VP and Elta CEO Yoav Tourgeman said: “IAI is pleased to sign this cooperation agreement with our partners in Abu Dhabi. Coronavirus disease crosses continents, peoples and religions and we see paramount importance in the cooperation that will deliver breakthrough solutions. The Israeli Air Force recently joined the fight against the Coronavirus on the basis of the technological know-how, capabilities and daring in the aerospace industry since its inception.”
With the spread of the Covid-19 virus worldwide, the aerospace industry has begun to explore various options of assistance needed at the national level in Israel and to offer breakthrough technological solutions. Since the coronavirus eruption in Israel, the aerospace industry has been collaborating with health and security agencies as well as a member of the Government Authority’s initiative to understand the evolving needs of the fight.
Elta is a world leader in remote sensing and radar, develops breakthrough systems and strategies such as mission aircraft, national cyber systems, terrestrial robotics, hover protection, homeland defense systems, and more. It is involved in satellites, unmanned vehicles, civil aviation and cyber.
Israel Aerospace Industries (IAI) entered a historic collaboration agreement with Group42, a company based in Abu-Dhabi, the capital of the United Arab Emirates. The collaboration between the two companies will cover research and development of solutions that may help fight the COVID-19 pandemic.
The agreement was signed between IAI’s ELTA Group via a video conference call between UAE and Israel. In the call, representatives of both companies discussed ways to leverage AI and other innovative technologies including lasers and sensors, to develop new COVID-19 focused systems. The solutions, as well as the joint medical and technological initiatives, are meant to help not only the populations of both countries but also aid in the global battle against the COVID-19 pandemic and improve the healthcare situation of the entire region.
WAM Emirates media release
Group 42 (G42), a leading technology company based in Abu Dhabi, announced today it has signed Memoranda of Understanding with Rafael Advanced Defense Systems, Rafael, and Israel Aerospace Industries.
Executives from each company took part in a signing ceremony held via video conference between the UAE and Israel. During the event, they discussed how they might capitalise on their respective expertise and technologies to develop cutting-edge solutions and medical initiatives that would benefit, not only the populations of both countries, but humanity as a whole.
The CEO of Group 42, said: “At G42, we embrace international cooperation as a way to develop new and innovative technological solutions for the public good. The UAE has led by example in the global collaborative effort to defeat the Covid-19 pandemic, and our company is privileged to follow the lead and share resources and expertise with Rafael and IAI for such a significant cause.”
G42 has been at the forefront of the battle against COVID-19 since the outbreak began. Thanks to its expertise in AI-driven genomics, the company has recently announced the development, in partnership with UK’s Oxford Nanopore Technologies, of an end-to-end detection solution with ultra-high throughput to screen en masse and on demand, facilitating the re-opening of global economies.
In the UAE, G42 is also trialing the world’s first phase III clinical trial of a COVID-19 inactivated vaccine, under the supervision of the Department of Health of Abu Dhabi.
Document 3 Rafael
Ariel Karo, EVP business development, Rafael: “This is a historic cooperation that was born out of a global crisis”. As a technological leader, particularly in the AI field, we are proud to offer our range of capabilities and knowhow to help in the fight against the COVID 19.
Froom the very beginning of the Corona crisis, seven of RAFAEL’s development teams have been deployed at 11 Israeli hospitals, working non-stop to utilize and implement advanced technologies in the fight against COVID-19. Following a comprehensive review and mapping of the most critical needs, our efforts became focused on two main goals: Protecting the medical staff from infection through technological solutions ‒ and rapidly developing solutions that can be tested and implemented in a matter of days ‒ not weeks or months. These goals are being achieved in record time, using a variety of technologies ‒ thanks to the selfless dedication of RAFAEL employees who are putting heart and soul into repurposing the company’s most useful technologies to create these urgently-needed solutions.
Rafael Advanced Defense Systems Ltd. and Group 42 (G42), a leading technology company based in Abu Dhabi, announced today the signing of two distinct Memoranda of Understanding to explore collaborations in the research and development of effective solutions to combat SARS-CoV-2, the virus that causes COVID-19 disease.
Executives from each company took part in a signing ceremony held via video conference between the UAE and Israel. During the event, they discussed ways of leveraging their respective expertise to develop cutting-edge solutions and medical initiatives that could not only benefit the population of the two countries, but humanity as a whole.
Mr. Peng Xiao, CEO of Group 42, said: “At G42, we embrace international cooperation as a way to create better and more effective technologies for the public good. The UAE has led by example in the global collaborative effort to defeat the Covid-19 pandemic, and our company is privileged to follow the lead and share resources and expertise with Rafael and IAI for such a significant cause.”
BG (ret.) Ariel Karo, Rafael EVP for Marketing and Business Development: “This is a historic collaboration that was born out of a global crisis. As a technological leader, particularly in the field of AI, we are proud to offer our range of capabilities and knowhow to help in the fight against the COVID-19.”
This joint initiative brings together some of the region’s most active players in the response to COVID-19, and aims to combine their respective knowledge, personnel, technology, and resources to conceptualize, develop, and optimize breakthrough solutions that will help the world safeguard public health and defeat Covid-19.
G42 has been at the forefront of the battle against COVID-19 since its outbreak. Thanks to its expertise in AI-driven genomics, the company has recently announced a new partnership with UK’s Oxford Nanopore Technologies for the joint development of an end-to-end detection solution to screen in mass and on demand, in an effort to support the re-opening of global economies. In the UAE, G42 is also operating the world’s first phase III clinical trial of a COVID-19 inactivated vaccine, under the supervision of the Abu Dhabi Department of Health.
With a legacy of over 72 years, Rafael Advanced Defense Systems is a national center of research and development through its wide range of cutting-edge technologies. During the global COVID-19 pandemic, Rafael had swiftly developed a range of solutions to help society function in this current state. Some of these systems include robotic systems for hospitals, thermic sensors to remotely-detect body temperature, a unique “splitter” for ventilators to use on two patients simultaneously, a medical data streaming app, big-data and AI technologies, and more.